Nature Reviews Drug Discovery (2020) https://doi.org/10.1038/s41573-020-0068-6 Published online 11 June 2020
In Figure 1, gefitinib was misspelled and gefitinib and erlotinib were mislabelled as mAbs. In the main text, GDC-0994 was incorrectly called GDC-0944 in one instance and GDC-0094 in one instance. These corrections have been made to the online version of the article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Moore, A.R., Rosenberg, S.C., McCormick, F. et al. Author Correction: RAS-targeted therapies: is the undruggable drugged?. Nat Rev Drug Discov 19, 902 (2020). https://doi.org/10.1038/s41573-020-0089-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41573-020-0089-1
This article is cited by
-
Multifunctional RGD coated a single-atom iron nanozyme: A highly selective approach to inducing ferroptosis and enhancing immunotherapy for pancreatic cancer
Nano Research (2024)
-
Transcriptome Analysis Reveals the Anti-Tumor Mechanism of Eucalyptol Treatment on Neuroblastoma Cell Line SH-SY5Y
Neurochemical Research (2022)
